Researchers and policymakers must challenge the default framing and stereotypical minority myth mindset which uniformly classifies AANHPI communities as low-risk, hindering both visibility and resource allocation.
While the drop in drug overdose deaths is promising, and could potentially be partially attributed to the efforts of the federal government, we must remain cognizant about the sheer number of lives we continue to lose every year to overdose.
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
Through a new partnership, Bicycle Health providers can prescribe patients buprenorphine extended release injections (otherwise known as Sublocade), which can be administered by a pharmacist at an Albertsons pharmacy.
Patients with opioid use disorder are more likely to stick with their treatment plan when offered buprenorphine via telemedicine, according to a new study. The study involved 1,378 patients, and their 180-day treatment retention rate was 56.4%.
Medications that treat opioid use disorder (OUD) — such as methadone, buprenorphine and extended-release naltrexone — are proven to save lives. However, a new study revealed that less than 15% of Americans with OUD receive these medications. Its lead author laid out three actions the U.S. should prioritize to increase access.
The reSET-O prescription mobile application is directed at supporting patients using buprenorphine as a medicinal aid in treatment to overcome opioid addiction.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.
The Psychopharmacologic Drugs Advisory Committee will meet on Thursday to vote on whether to recommend the FDA approve the drug, ALKS 5461, an opioid for major depressive disorder.